Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Federal Trade Commission
Queensland Health

Generated: March 22, 2018

DrugPatentWatch Database Preview

Claims for Patent: 4,837,223

« Back to Dashboard

Summary for Patent: 4,837,223
Title: (S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide compositions
Abstract:(S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide, its preparation and pharmaceutical compositions containing the same. It can be prepared either by reacting (S)-alpha-ethyl-2-oxo-1-pyrrolidineacetic acid successively with an alkyl haloformate and with ammonia, or, by cyclizing an (S)-2-amino-butanamide of the formula X--CH.sub.2 CH.sub.2 -NHCH (C.sub.2 H.sub.5)CONH.sub.2 wherein Y is a --CH.sub.2 --radical when X represents a ZOOC--radical and Y is a --CO-- radical when X represents a HalCH.sub.2 --radical, Z being a C.sub.1 -C.sub.4 alkyl radical and Hal a halogen atom. This laevorotatory enantiomer has been found to have significantly higher protective activity against hypoxia and ischemia than the corresponding racemate.
Inventor(s): Gobert; Jean (Brussels, BE), Geerts; Jean-Pierre (Leglise, BE), Dodson; Guy (Bellefontaine, BE)
Assignee: UCB Societe Anonyme (Brussels, BE)
Application Number:07/025,277
Patent Claims: 1. A pharmaceutical composition comprising a therapeutically effective amount of (S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and a pharmaceutically acceptable solid or liquid diluent or carrier therefor, said composition being substantially free of (R)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide.

2. (S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide substantially free of (R)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide, prepared by the process which comprises cyclizing, in an inert solvent and in the presence of a basic substance, an (S)-2-amino-butanamide of the formula

in which

X represents ZOOC-- or HalCH.sub.2 --, wherein Z is alkyl of 1 to 4 carbon atoms and Hal a halogen atom, and

Y represents --CH.sub.2 -- or --CO--,

with the proviso that Y is --CH.sub.2 -- when X represents ZOOC--, and Y is --CO-- when X represents HalCH.sub.2 --.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.